contact us

PLEASE DO NOT LEAVE ANY CONFIDENTIAL TREATMENT DATA, PRIVATE PATIENT DETAILS OR ANY OTHER PROTECTED HEALTH INFORMATION (PHI) ON THIS SITE. THIS IS IN ORDER TO ENSURE PRIVACY AND REGULATORY COMPLIANCE WITH APPLICABLE PRIVACY RULES AND LAWS (INCLUDING BUT NOT LIMITED TO HIPAA).
Unsubscribe From Our Mailing List

New Hope for Your Post Traumatic Stress Disorder (PTSD)

Image

Take Part in an FDA Approved Study for PTSD with the latest Deep TMS Technology

About BrainsWay’s technology (Deep TMS)

BrainsWay* Deep TMS is an innovative, revolutionary technology for the treatment of brain disorders such as PTSD. Deep TMS non-invasively stimulates the brain regions responsible for PTSD using brief magnetic fields, at an amplitude similar to that used in magnetic resonance imaging (MRI) systems. The device has been cleared by the FDA for treating depression, and has been studied in over 60 clinical trials around the world.

The treatment does not entail systemic side effects, which are effects deriving from medication entering the bloodstream and circulating throughout the body.

BrainsWay Deep TMS treatment requires only brief daily sessions over a few weeks, without indefinite or permanent medication intake.

About the Study

The study aims to test the safety and efficacy of Deep TMS for patients suffering from PTSD who have not sufficiently benefitted from their current treatment. The treatment will take place in leading medical centers around the world and is administered by experts. It entails no surgery, hospitalization or medications, and is based on 12 brief sessions of less than 20 minutes over a period of 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits. During the treatment, the patient is comfortably seated in a chair, and a cushioned helmet placed over the head generates brief magnetic fields.

Immediately after each session, patients can drive home independently and resume their daily routine. Patients can continue their current behavioral or medication treatment during the study. The study has been approved by the FDA.

Participant Criteria

Study participants should meet the following criteria: Aged 22-68, diagnosed with PTSD with partial or no response to treatment and have not had any prior TMS treatment.

If you have been diagnosed with PTSD, you may be eligible for the study.

Study Locations

Advanced Mental Health Care Inc. – Juno Beach, Florida, USA
Contact information: Elyssa Sisko, 561-2678876, elyssasisko@gmail.com

Advanced Mental Health Care Inc. – Royal Palm Beach, Florida, USA
Contact information: Elyssa Sisko, 561-2678876, elyssasisko@gmail.com

Yellowbrick Consultation and Treatment Center – Illinois, USA
Contact information: Matt Graller, 847-8691500 ext 202, mgraller@yellowbrickprogram.com

Center for Addiction & Mental Health (CAMH) – Toronto, Canada
Contact information: Mawahib Semeralul, 416-535-8501 ext. 30210, Mawahib.Semeralul@camh.ca

Advanced Mental Health Care Inc.- Palm Beach, Florida, USA
Contact information: Elyssa Sisko, 561-333-8884, elyssasisko@gmail.com / Aron Tendler, M.D., 561-3338884, aron.tendler@gmail.com

TMS Hope Center of Long-Island – New York, New York, USA
Contact Information: Kyle Lapidus, 631-509-6111, kylelapidus@gmail.com

Medical University Of South Carolina (MUSC) – Charleston, South Carolina, USA
Contact information: Scott Henderson, 843-792-5560, henderjs@musc.edu

Kadima Neuropsychiatry – San Diego, California, USA
Contact information: David Feifel, M.D., 858-412-4130, dfeifel@kadimanp.com

Beer Yaakov, Israel

Contact information: Dr. Arye Sofer / Danielle Warzager : danielle.warzager@MOH.GOV.IL, + 972 (0)8-9258396/ +972 (0)8-9258474